News - Abzena

Filter by year

Filter by topic

Abzena takes on new facilities in Cambridge, UK and San Diego

Cambridge, UK 5 January 2018 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities. In Cambridge, UK, the Group’s lease has commenced for 30,000 square feet of space in […] Read more

Babraham Bioscience Technologies “Technology Development Laboratory” (TDL) moves to Abzena

Cambridge, UK, 5 January 2018 – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has entered into an agreement with Babraham Bioscience Technologies Limited (BBT), the company that manages and develops the Babraham Research Campus, to run and develop the services formerly […] Read more

Abzena selects Sartorius Stedim Biotech to equip their U.S. based development and manufacturing sites in San Diego and Bristol

Goettingen, Germany, January 4, 2018 – Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as their preferred equipment supplier in the U.S. Abzena has selected Sartorius Stedim to equip their integrated CDMO facilities in Bristol, PA, for the development […] Read more

Half year results: Growth strategy progressing

Cambridge, UK, 12 December 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, publishes its half year results for the six months to 30 September 2017. Highlights Investment programme progressing in line with the growth strategy including: Upgrading of […] Read more

Abzena secures ADC manufacturing services contract

Cambridge, UK, 11 December 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (“ADC”) […] Read more

Abzena successfully secures over 25 chemistry and ADC service agreements

Bristol PA, USA, 4 December 2017 – Abzena is pleased to announce that their expert integrated Cambridge, UK and Bristol, PA chemistry teams have secured over 25 chemistry and ADC service agreements in the past 90 days. These service agreements span from complex synthetic organic chemistry, antibody drug conjugate (ADC), conjugation and BioNMR projects and […] Read more

Novel antibodies against a ground-breaking new target for the treatment of Cardiovascular Fibrosis developed by Enleofen Bio, with support from Abzena, featured in ‘Nature’ article

Cambridge, UK and Singapore, 14 November 2017 Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, works with Enleofen Bio Pte Ltd (‘Enleofen Bio’), to develop first-in-class antibody therapeutics for the treatment of fibrotic human diseases. The Founders of Enleofen Bio discovered […] Read more

Abzena and UGA Biopharma Partner to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis

CAMBRIDGE, England & HENNIGSDORF, Germany- Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, and UGA Biopharma GmbH, a cell line development specialist, announce the completion of the development of a biosimilar cell line to treat Multiple Sclerosis (MS). […] Read more

Abzena begins the installation of a new 500 L bioreactor at its San Diego facility

Abzena have begun the installation of a new 500L BIOSTAT® STR, single-use bioreactor, as part of a series of significant investments in its San Diego process development and manufacturing operations. This expansion is in response to a general demand in the marketplace and the need of current clients with clinical successes for larger volume production […] Read more

Abzena appoints Lotta Ljungqvist as Non-Executive Director

Cambridge, UK, 19 September 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that Lotta Ljungqvist has today been appointed as a Non-Executive Director of the Company. Lotta Ljungqvist has a broad range of commercial and directorial experience. […] Read more

Interested in our services? Get In Touch